Navigation Links
Archemix in Medical News

Alexandria Real Estate Equities Provides Update

...ical represented approximately 13% and were dominated by high-quality, leading-edge companies with blue chip venture investors, including Ambrx, Inc., archemix Corp., Fate Therapeutics, Inc., Juvaris BioTherapeutics, Inc. and TolerRx, Inc.; and the remainder of approximately 7% was comprised of traditional ...

Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

...icology studies for a number of biologic compounds, including monoclonal antibody immunoconjugates and nucleic acids at Millennium Pharmaceuticals and archemix Corp. Dr. Green will lead Taligen's development project teams for the company's two most advanced clinical candidates, TT30 and TA106, acros...

Isis Reports Financial Results and Highlights for Fiscal year 2007

...ction with Roche. * Isis licensed technology to archemix for aptamer drug applications in exchange for...s and royalties on aptamer drugs developed by archemix that incorporate Isis' proprietary chemistries or ...sis received the first milestone payment from archemix for the advancement of Archemix' aptamer drug into...
Archemix in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...velop drugs that incorporate Isis' technology resulting in financial benefits as these assets mature. Isis earned milestone payments from archemix and Alnylam because each company advanced drugs that incorporate Isis' technology. Isis co-exclusively licensed its single-stranded RNA interfe...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Archemix Announces Completion of Phase 1 Trial of ARC1779

... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - archemix Corp., a biotechnology company focused on discover...n as thrombotic thrombocytopenic purpura, or TTP. archemix plans to present a complete data set from this Pha...esized rather than biologically expressed. About archemix ...
Archemix in Biological Technology

Biotech Avoids Fall Out From Tough Quarter for Capital Markets

...Biotech IPOs on hold The prevailing tough economic environment also took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...

Biotech Drops Amid Tough Markets in February

...otech IPOs remain on hold The prevailing tough economic environment took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...
Other Tags
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. ... stress and family conflicts before surgery may face a ... study suggests. Investigators found that patients with a ... times greater risk for complications compared to those with ... long known that patient quality of life is a ...
(Date:9/19/2014)... "I have difficulty putting in my eye contacts, ... skin around my eyes during the struggle," said an ... a more convenient method of performing this task." , ... easier, more sanitary method of putting in contact lenses. ... saves time and effort, and helps prevent wrinkles around ...
(Date:9/19/2014)... of Mayo Clinic have discovered a defect in a ... of toxic protein in the brains of Alzheimer,s ... between neurons both significant contributors to this type ... of Neuron , offers the potential ... or rescue this pathway," says the study,s lead investigator, ...
(Date:9/19/2014)... 19, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, IX Web Hosting and Bluehost are ... “As is known to most people, VPS (Virtual ... physical server computer into many servers, each of ... on someone’s own dedicated computer,” the manager of ...
(Date:9/19/2014)... 19, 2014 BCC Research reveals in ... GLOBAL MARKETS , the global market for human antifungal ... by 2018, with a five-year compound annual growth rate ... growing at a steady 3.8% CAGR. , Given the ... sales, coupled with the incidence of increasing mortality and ...
Breaking Medicine News(10 mins):Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
(Date:9/18/2014)... of Americans to undertake jaunts into the countryside each year ... within a century, according to new research. , Climate change ... United States as summer temperatures linger later into the year, ... and Biogeography . For instance, the paper birch a ... Hampshire could change color one to three weeks later ...
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
Other Contents